Cellebrite DI Ltd [CLBT] stock is trading at $18.48, up 1.32%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLBT shares have gain 2.38% over the last week, with a monthly amount glided 9.74%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cellebrite DI Ltd [NASDAQ: CLBT] stock has seen the most recent analyst activity on March 28, 2024, when Needham reiterated its Buy rating and also boosted its price target to $13.50 from $13. Previously, William Blair upgraded its rating to Outperform on March 13, 2024. On February 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $12 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $11 on July 19, 2023. William Blair downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to Neutral for this stock on August 12, 2022, and downed its price target to $6. In a note dated February 24, 2022, JP Morgan initiated an Overweight rating and provided a target price of $10.50 on this stock.
Cellebrite DI Ltd [CLBT] stock has fluctuated between $6.51 and $18.75 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Cellebrite DI Ltd [NASDAQ: CLBT] shares were valued at $18.48 at the most recent close of the market. An investor can expect a potential return of 8.23% based on the average CLBT price forecast.
Analyzing the CLBT fundamentals
Cellebrite DI Ltd [NASDAQ:CLBT] reported sales of 362.49M for the trailing twelve months, which represents a growth of 24.82%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at -0.27%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -78.15 and Total Capital is 0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.13 points at the first support level, and at 17.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.66, and for the 2nd resistance point, it is at 18.85.
Ratios To Look Out For
For context, Cellebrite DI Ltd’s Current Ratio is 1.73. Also, the Quick Ratio is 1.69, while the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 10.61.
Transactions by insiders
Recent insider trading involved YOSEF CARMIL, Officer, that happened on Oct 15 ’24 when 0.16 million shares were purchased. Officer, YOSEF CARMIL completed a deal on Sep 16 ’24 to buy 100000.0 shares. Meanwhile, Officer Ben-Peretz Leeor bought 8919.0 shares on Sep 04 ’24.
